SCHEMBL3500074

SCHEMBL3500074

[CH]=CC=CC=CC=[CH]

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL187821 0.94
SCHEMBL187820 0.94
SCHEMBL817833 0.78 ALDH1A1 (0.44)
SCHEMBL816869 0.78 ALDH1A1 (0.44)
SCHEMBL820235 0.78
SCHEMBL817397 0.78 ALDH1A1 (0.44)
SCHEMBL137814 0.78
SCHEMBL817679 0.78
SCHEMBL7363324 0.78
SCHEMBL816874 0.78 ALDH1A1 (0.44)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11744830-B2 Ameliorative agent for cytokine release syndrome and so on TORII PHARMACEUTICAL CO., LTD. (JP) 2023-09-05 US disclosed
US-20210128550-A1 AMELIORATIVE AGENT FOR CYTOKINE RELEASE SYNDROME AND SO ON TORII PHARMACEUTICAL CO., LTD. (JP) 2021-05-06 US disclosed
EP-3782625-A1 AGENT FOR IMPROVING CYTOKINE RELEASE SYNDROME, ETC TORII PHARMACEUTICAL CO., LTD. (JP) 2021-02-24 EP disclosed
CN-112105362-A Ameliorating agent for cytokine release syndrome and the like 鸟居药品株式会社 2020-12-18 CN disclosed
US-20100152301-A1 Treatment of Viral Infections GOVERNMENT OF THE US, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) 2010-06-17 US disclosed
EP-1976497-A2 TREATMENT OF VIRAL INFECTIONS THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) 2008-10-08 EP disclosed
WO-2007065007-A9 TREATMENT OF VIRAL INFECTIONS US HEALTH (US) 2007-09-13 WO disclosed
WO-2007065007-A2 TREATMENT OF VIRAL INFECTIONS GOVERNMENT OF THE U.S.A., AS REPERSENTED BY THE SECRETARY, DEPT. OF HEALTH AND HUMAN SERVICES (US) 2007-06-07 WO disclosed
US-RE39088-E1 Amide compounds and use of the same JAPAN TOBACCO, INC. (JP) 2006-05-02 US disclosed
WO-2006017369-A2 USE OF A FARNESYL TRANSFERASE INHIBITOR IN THE TREATMENT OF VIRAL INFECTIONS GOVERNMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) 2006-02-16 WO disclosed
US-5616803-A EXHIBIT SQUALENE SYNTHASE-INHIBITORY ACTIVITIES; USEFUL IN TREATMENT AND PROPHYLAXIS OF HYPERCHOLESTEREMIA, HYPERLIPEMIA AND ARTERIOSCLEROSIS BANYU PHARMACEUTICAL CO., LTD. (JP) 1997-04-01 US disclosed
US-5606101-A INTERMEDIATES FOR SQUALENE SYNTHASE INHIBITORS BANYU PHARMACEUTICAL CO., LTD. (JP) 1997-02-25 US disclosed
WO-1997001275-A1 COMBINATIONS OF INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE MERCK & CO., INC. (US) 1997-01-16 WO disclosed
US-5534654-A ANTITUMOR, ANTIINFLAMMATORY, INHIBITOR OF LYMPHOCYTE ADHESIVE FACTORS SHIONOGI & CO., LTD. (JP) 1996-07-09 US disclosed
EP-0696585-A1 NOVEL BISOXADIAZOLIDINE DERIVATIVE YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) 1996-02-14 EP disclosed
US-5489662-A Process for the preparation of organosilicon polymer TOSHIBA SILICONE CO., LTD. (JP) 1996-02-06 US disclosed
US-5488149-A SQUALENE SYNTHASE INHIBITORS AS ANTICHOLESTEROL OR ANTILIPEMIC AGENTS BANYU PHARMACEUTICAL CO., LTD. (JP) 1996-01-30 US disclosed
EP-0641820-A1 Process for the preparation of organosilicon polymer TOSHIBA SILICONE CO., LTD. (JP) 1995-03-08 EP disclosed
EP-0611749-A1 Substituted amic acid derivatives useful for treatment of arteriosclerosis BANYU PHARMACEUTICAL CO., LTD. (JP) 1994-08-24 EP disclosed
EP-0570594-A1 HYDROXAMIC ACID DERIVATIVE BASED ON AROMATIC SULFONAMIDE SHIONOGI & CO., LTD. (JP) 1993-11-24 EP disclosed